VEGFA and cancer: The experimental results are controversial though, as enzastaurin, another PKC inhibitor with known antiproliferative and proapoptotic effects in a variety of cancers has been shown to potentiate platelet aggregation and VEGF secretion thereby counteracting its anticancer potential [254].